iShares MSCI Indonesia ETF (EIDO) Stock Price Today
Aura AI Summary
Key Stats
- -Market Cap
- -Volume
- -Sector
- $19.2252W High
- $10.8052W Low
- -Typical Hold Time
- -Enterprise Value
- -Div Yield
- -Trading Activity
Track iShares MSCI Indonesia ETF (EIDO) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, iShares MSCI Indonesia ETF has traded between a low of $10.8 and a high of $19.22, highlighting its annual price range. Buy and sell iShares MSCI Indonesia ETF shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Most Recent News
AI use in cybersecurity jumps to 78% in 2026, but governance and failures lag behind.
The 2026 SANS AI Survey reveals rapid AI adoption in cybersecurity, with 78% of organizations using AI, up from 50% last year. However, governance structures and formal audit frameworks have not kept pace, leading to increased AI-related failures in ...

Head and neck squamous cell carcinoma market to grow 10.5% CAGR through 2036 with new immunotherapies.
The head and neck squamous cell carcinoma (HNSCC) market is projected to grow at a 10.5% CAGR from 2026 to 2036, driven by rising cancer incidence and new immunotherapy launches. Key emerging therapies from companies like Johnson & Johnson, BioNTech,...

Alamar Biosciences launches national study analyzing 21,000 plasma samples to advance Alzheimer's biomarkers.
Alamar Biosciences has partnered with top U.S. research universities to start a nationwide proteomics project using its NULISAseq™ Neuro 220 panel. The study will analyze about 21,000 plasma samples from 10,000 Alzheimer's and related dementia partic...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.